Pay in 4 interest-free payments of $7.13 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
#Cipla #EliLilly #Yurpeak #Tirzepatide #DiabetesCare #ObesityManagement #Endocrinology #InternalMedicine #HealthcareProfessionals #PharmaNews #MedicalInnovation #CaringForLife #PatientCare #PharmaLeadership #HealthcareIndia Cipla has the rights to distribute and promote Yurpeak, a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, indicated as an adjunct to diet and exercise for the treatment of type 2 diabetes and chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity
200 (Pt 2): 193202
Abbass NJ, Nahlawi R, Shaia JK, Allan KC, Kaelber DC, Talcott KE, et al
Plans across government and employers are pulling back support
